Chimeric Therapeutics (ASX:CHM) posts 40% tumour shrinkage at top dose in CAR-T trial

Stable Disease held for six months turns a Phase 1 signal into a data point worth pricing

Cell therapy microcap Chimeric Therapeutics (ASX:CHM) has delivered the kind of interim data update small-cap biotech investors actually want to see. Two of four patients dosed at the highest level of its CHM CDH17 Phase 1 trial have shown tumour shrinkage of 17% to 40% in individual lesions, with Stable Disease maintained for six and four months respectively.

For a CAR-T therapy targeting solid tumours in the gut, that is a genuinely meaningful signal. Solid tumour CAR-T has been the graveyard of a lot of biotech capital over the past decade, so any evidence of durable disease control at the top dose deserves attention.

CDH17 is a cancer marker linked to poor outcomes in colorectal, gastric and neuroendocrine tumours, exactly the indications where standard chemotherapy runs out of runway quickly. The Phase 1/2 study, invented in the lab of Dr Xianxin Hua at the University of Pennsylvania, is now four patients into Dose Level 3 of 450 million CAR-T cells, with a fifth manufactured and ready to dose in the coming weeks.

Why 17 to 40% tumour shrinkage is a bigger deal than it reads

Numbers like 17% and 40% look modest on paper. In the world of relapsed and refractory gastrointestinal cancer, they are not.

These are patients who have already failed at least one line of standard therapy. Historically, response rates in this setting sit in the single digits, so any tumour shrinkage measured under RECIST 1.1 (the standard imaging framework oncologists use to judge whether tumours are growing, shrinking, or holding steady) is a signal worth paying for.

Stable Disease held for six months in one patient and four months in another is the sort of data that starts to interest big pharma business development teams, particularly for a first-in-class 3rd generation CAR-T asset with a defensible target.

The safety picture is holding, which is the other half of the story

One dose-limiting toxicity was reported back on 31 May 2026 and no additional safety signals have emerged since. For a solid tumour CAR-T at the top dose level, that is a reassuring read.

The bear case on CAR-T in solid tumours has always been that efficacy comes with unacceptable toxicity. Chimeric’s data so far pushes back on that narrative without eliminating it, and the market will want the remaining two Dose Level 3 patients to confirm the pattern before rerating the stock in earnest.

The funding line buried in the announcement

One sentence in today’s release deserves more attention than it will get. The sixth and final patient will be dosed by the end of 2026, subject to funding.

We think this is the single most important operational detail in the update. For a clinical-stage cell therapy company with multiple programs, the phrase ‘subject to funding’ tells investors a capital raise is likely between now and year-end. Our concern is that a discounted placement lands before the full Dose Level 3 dataset does, which would blunt the rerating this data deserves.

The Investors Takeaway for Chimeric Therapeutics

The clinical story is heading in the right direction. Two more Dose Level 3 patients still need to read out, but 17 to 40% tumour shrinkage and multi-month Stable Disease at the top dose is a meaningful base to build from in solid tumour CAR-T.

The commercial story now depends on two things. First, whether the remaining Dose Level 3 data confirms the signal and enables a recommended Phase 2 dose. Second, whether Chimeric can bridge to that catalyst without a heavily dilutive raise. Readers can find our earlier coverage of the licensing angle at stocksdownunder.

The next data drop and the next funding announcement are the two events that matter, and the order in which they arrive will shape the share price more than the data itself.